Millions of Americans who take blood pressure medications also reach for green tea, licorice supplements, or St. John’s wort, often assuming these products are harmless because they are sold without a prescription. Pharmacokinetic studies now show that some of these combinations can slash drug absorption by more than 60 percent or push blood pressure higher through entirely separate biological pathways. The result is a growing gap between the dose a doctor prescribes and the dose that actually reaches a patient’s bloodstream, a gap that routine checkups may not catch until blood pressure readings drift upward.
How green tea and licorice quietly undermine blood pressure control
The clearest warning signal comes from controlled studies on green tea and two of the most widely prescribed antihypertensive drugs. A study published in Clinical Pharmacology and Therapeutics found that green tea decreased nadolol exposure in healthy subjects by roughly 85 percent, dramatically lowering both peak plasma concentration and overall drug levels. Nadolol is a beta-blocker used to lower heart rate and blood pressure; losing that much of the drug from the bloodstream could leave a patient functionally unmedicated even while taking every pill on schedule.
A separate controlled trial published in Clinical and Translational Science tested green tea catechins alongside lisinopril, one of the most commonly prescribed ACE inhibitors in the United States. The researchers reported geometric mean ratios of approximately 0.289 for peak concentration and 0.337 for total drug exposure compared with control subjects who received lisinopril without green tea. In practical terms, green tea cut the amount of lisinopril reaching the bloodstream by roughly two-thirds. For a patient already titrated to a specific dose, that reduction could translate into persistently elevated readings at clinic visits, even though the patient appears fully adherent.
Licorice poses a different but equally disruptive problem. Rather than blocking drug absorption, excessive licorice intake triggers sodium and water retention, raises blood pressure on its own, and suppresses the renin-aldosterone system. A report in The New England Journal of Medicine documented that this mechanism can produce clinically significant hypertension and dangerously low potassium levels. A patient taking an antihypertensive while consuming licorice-containing supplements may find that the drug cannot keep pace with the supplement’s opposing effect on blood pressure, especially if the licorice is taken daily in teas, candies, or herbal capsules.
These examples highlight two distinct kinds of interference: one where an herb reduces the amount of drug that ever reaches the circulation, and another where a supplement acts as a pharmacologic antagonist, nudging blood pressure higher despite appropriate prescribing. In both cases, the numbers on the pill bottle no longer match the dose that the body actually experiences.
St. John’s wort, grapefruit, and the enzyme pathways that amplify risk
Green tea and licorice are not the only offenders. The U.S. Food and Drug Administration has warned that combining supplements with medications can reduce the effectiveness of multiple drug classes, in part because certain herbs accelerate the enzymes that break down medications in the liver and gut. St. John’s wort is a prime example: it induces drug-metabolizing enzymes and transporters, which can lower blood levels of many prescription drugs.
The NIH National Center for Complementary and Integrative Health notes that St. John’s wort interacts with digoxin, ivabradine, and warfarin, all of which are used in cardiovascular care. These interactions can either blunt the intended effect-such as weakening rate control in atrial fibrillation-or destabilize anticoagulation. The FDA also lists St. John’s wort and curcumin as substances that interact with CYP enzymes and transporter systems, the same molecular machinery that determines how much of a heart drug survives first-pass metabolism. For patients with hypertension who also have arrhythmias, heart failure, or coronary disease, the stakes of such interactions are high.
Grapefruit juice works through almost the opposite mechanism. Instead of speeding drug clearance, it inhibits the CYP3A4 enzyme in the intestinal wall, allowing more of certain drugs to enter the bloodstream than intended. The FDA has stated that grapefruit can raise blood levels of medications including nifedipine, a calcium channel blocker prescribed for hypertension. Higher-than-expected drug levels increase the risk of side effects such as dizziness, flushing, and dangerous drops in blood pressure.
Where green tea starves the body of a needed drug, grapefruit floods it with too much. The result can be episodes of lightheadedness or fainting that seem unpredictable to patients and clinicians, especially if grapefruit is consumed only intermittently. Because the interaction is driven by enzyme inhibition in the gut, even a single large glass of juice can have effects that last more than a day.
Hawthorn, an herbal extract marketed for heart health, adds another layer of uncertainty. A human interaction study published in The Journal of Clinical Pharmacology tested hawthorn alongside digoxin, a narrow-therapeutic-index cardiac drug where small changes in blood levels can trigger toxicity or treatment failure. Although digoxin is not a standard blood pressure pill, the study illustrates how even “gentle” herbal products can shift the pharmacokinetics of drugs that require precise dosing. For patients taking multiple cardiovascular medications, adding hawthorn without medical supervision may create unpredictable combinations of effects.
Gaps in real-world data
Despite the clear signals from controlled pharmacology studies, real-world data on how often these interactions harm patients remain limited. Many clinical trials of antihypertensive drugs exclude people who regularly drink large amounts of green tea, use herbal supplements, or consume grapefruit juice, leaving a blind spot in the evidence base. Observational studies, meanwhile, often rely on self-reported supplement use, which can be incomplete or inaccurate.
Electronic health records rarely capture over-the-counter products with the same rigor as prescription drugs. A patient may tell a pharmacist about St. John’s wort or licorice tea, but that information might never be documented in a way that allows researchers to link it to treatment failures or adverse events. When blood pressure creeps up or side effects appear, clinicians understandably focus on adjusting drug doses or adding new medications rather than tracing the problem back to a seemingly benign beverage or supplement.
Underreporting further clouds the picture. Patients who believe that “natural” products are inherently safe may not mention them during office visits, especially if they anticipate disapproval. Clinicians, pressed for time, may not ask detailed follow-up questions about teas, energy drinks, or herbal blends. As a result, many herb–drug interactions likely go unrecognized, recorded only as “resistant hypertension” or “intolerance” to a particular medication.
Still, the mechanistic data are strong enough to warrant caution. When a controlled trial shows that green tea can reduce exposure to a blood pressure drug by two-thirds, it is reasonable to suspect that similar effects may occur in everyday life, even if large epidemiologic studies have not yet quantified the risk. Likewise, the well-characterized enzyme effects of St. John’s wort and grapefruit make it plausible that some unexplained blood pressure variability or side effects in practice stem from these products.
What patients and clinicians can do now
Until better real-world data emerge, the safest course is to treat supplements and functional foods with the same respect as prescription drugs. Patients taking antihypertensives should be encouraged to bring all pill bottles, teas, and powders to clinic visits, including products purchased online or at health food stores. A brief, nonjudgmental conversation about green tea, licorice, St. John’s wort, and grapefruit can surface potential problems before they translate into uncontrolled blood pressure or side effects.
Clinicians may consider asking more targeted questions when blood pressure control does not match expectations. Has the patient recently started drinking several cups of green tea a day? Are they using licorice-containing supplements for digestion or cough? Have they added a “mood” herb that might be St. John’s wort? Do they drink grapefruit juice with breakfast? These specifics can be more revealing than a general query about “herbal products.”
Pharmacists, too, have a critical role. Because they see both prescription and over-the-counter purchases, they are well positioned to flag combinations that raise concern. Counseling at the point of sale-especially when patients pick up new blood pressure prescriptions-can prevent risky pairings from becoming entrenched habits.
Ultimately, the message is not that patients must avoid every cup of green tea or every herbal supplement, but that these choices should be made with an understanding of their potential to alter drug levels and blood pressure. As the science of pharmacokinetic interactions continues to evolve, recognizing the hidden power of everyday beverages and botanicals is an important step toward safer, more effective hypertension care.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
